Home / Guidelines


India to revise ‘similar biologics’ guideline

The Indian Ministry of Health is planning to revise its guidelines for approving ‘similar biologics’. The ministry aims to make the regulatory pathway more robust and to align the guidelines further with global guidelines for biosimilars.

GPhA challenges FDA guidance on size and shape of generic pills

In June 2015, the US Food and Drug Administration (FDA) published guidance on the size, shape and other physical attributes of generic tablets and capsules [1]. However, the Generic Pharmaceutical Association (GPhA) has raised a number of concerns about the guidance.

FDA to hold public meeting on reauthorization of BsUFA

The US Food and Drug Administration (FDA) is seeking specific suggestions on potential changes to the Biosimilar User Fee Act (BsUFA) performance goals ahead of negotiations to reauthorize the law.

FDA defends lack of biosimilars guidelines

The US Food and Drug Administration’s (FDA) director for the Center for Drug Evaluation and Research (CDER) Dr Janet Woodcock, told senators on 17 September 2015 that a critical part of launching a robust US biosimilars market and setting up the regulations to support it is to make sure the scientific framework is ‘bulletproof’.

FDA issues draft guidance on naming biologicals

The US Food and Drug Administration (FDA) has issued another draft guidance for biosimilars. The draft guideline, issued on 27 August 2015, details the FDA’s proposal on the non-proprietary naming of biological products.

FDA releases 48 new and revised bioequivalence guidelines for generics

The US Food and Drug Administration (FDA) has released 44 new draft guidance documents and four revisions to guidance documents on bioequivalence requirements for the development of generics containing 46 different active ingredients. 

FDA wants generics to be physically same as originators

Until now generics have been required to be pharmaceutically equivalent and bioequivalent to the brand-name drug, however, generics made by different manufacturers could differ substantially from their brand-name therapeutic equivalents and from each other in their physical appearance, e.g. colour, shape or size of pills. The US Food and Drug Administration (FDA), aims to change this, with guidance issued in June 2015 recommending that the physical properties, including the size, shape and colour, of generics should be similar to those of their reference drugs.

US guidelines for generics

Last update: 14 August 2015

The regulatory body for approval of medicines in the US is the Food and Drug Administration (FDA).

Australia implements EMA’s biosimilars guidelines

The Therapeutic Goods Administration (TGA), Australia’s regulatory body for therapeutic goods, announced on 3 June 2015 that it had adopted ten European Union (EU) guidelines in Australia.

Australian guidelines for biosimilars

Last update:  7 August 2015

The regulatory body for therapeutic goods in Australia is the Therapeutic Goods Administration (TGA).

Generics News Research General


Biosimilars News Research General